Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–14 of 14 results
Advanced filters: Author: Jason Grebely Clear advanced filters

  • HCV mixed infection and reinfection occur commonly in people who inject drugs (PWID). The authors review the epidemiology, natural history and methods used to detect mixed HCV infection in PWID. The potential effect of mixed infection and reinfection on treatment outcomes is discussed, as well as how future studies should be designed in the era of direct acting antiviral treatment of HCV.

    • Evan B. Cunningham
    • Tanya L. Applegate
    • Jason Grebely
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 12, P: 218-230

  • Direct-acting antiviral agents (DAAs) are highly effective treatments for HCV, but are not always accessible to people who inject drugs (PWID). Here, Grebely and colleagues outline the epidemiology of HCV in PWID, discuss current data on DAA outcomes in this population and highlight steps required to broaden access to HCV therapy with the eventual goal of HCV elimination.

    • Jason Grebely
    • Behzad Hajarizadeh
    • Gregory J. Dore
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 14, P: 641-651

  • Reducing the stigma and discrimination that people living with liver conditions experience requires rethinking how diagnoses, diseases, etiologies and circumstances are perceived — a shift that begins with the language used to name and describe them.

    • Jeffrey V. Lazarus
    • Dana Ivancovsky Wajcman
    • Marcela Villota-Rivas
    Comments & Opinion
    Nature Medicine
    P: 1-8

  • Assessment and uptake of hepatitis C treatment among injection drug users with HCV infection remains low, partly due to concerns regarding poor adherence and response to therapy. Findings from a large, prospective study demonstrate comparable adherence and response to hepatitis C treatment among nondrug users, former drug users and active drug users.

    • Jason Grebely
    • Gregory J. Dore
    News & Views
    Nature Reviews Gastroenterology & Hepatology
    Volume: 8, P: 11-13

  • Globally, 130–170 million people have HCV infection; however, distribution patterns are highly variable. This Review outlines the latest information on the epidemiology and natural history of HCV infection. The disease burden and mortality of HCV-related diseases, and the potential effect of HCV treatment on disease burden, are also outlined.

    • Behzad Hajarizadeh
    • Jason Grebely
    • Gregory J. Dore
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 10, P: 553-562

  • The asymptomatic nature of acute HCV infection and difficulties in identifying and following those at risk of acquiring infection has hampered our knowledge regarding treatment for this condition. This Review highlights current knowledge of the epidemiology, diagnosis, natural history and treatment of acute HCV infection, and includes proposed recommendations for the assessment and treatment of this infection.

    • Jason Grebely
    • Gail V. Matthews
    • Gregory J. Dore
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 8, P: 265-274

  • The World Health Organization’s targets for eliminating hepatitis C virus by 2030 have been deemed ambitious by many. However, we believe they are achievable, provided they are supported by global commitment.

    • Gregory J. Dore
    • Marianne Martinello
    • Jason Grebely
    Comments & Opinion
    Nature Medicine
    Volume: 26, P: 157-160

  • Chronic Hepatitis C infection is associated with a broad spectrum of liver pathologies, ranging from inflammation to fibrosis and liver cancer. Here Thabet et al. identified a polymorphism in the gene MBOAT7 that is associated with increased hepatic inflammation and higher risk of fibrosis development and progression.

    • Khaled Thabet
    • Anastasia Asimakopoulos
    • Rosanna Santaro
    ResearchOpen Access
    Nature Communications
    Volume: 7, P: 1-8

  • Direct-acting antiviral agents (DAAs) have revolutionized the management of chronic hepatitis C, but their use in acute infection is unclear. This Review outlines the epidemiology, diagnosis and management of acute HCV infection, providing insights into the use of DAAs in at-risk populations (such as people who inject drugs).

    • Marianne Martinello
    • Behzad Hajarizadeh
    • Gail V. Matthews
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 15, P: 412-424

  • Jacob George and colleagues examine whether the association of the IFNL3–IFNL4 region with hepatic inflammation and fibrosis is mediated by IFN-λ3 or IFN-λ4. They find greater hepatic inflammation, fibrosis progression rate and hepatic infiltration of immune cells in individuals with the risk haplotype that produces IFN-λ3 but not IFN-λ4.

    • Mohammed Eslam
    • Duncan McLeod
    • Rosanna Santoro
    Research
    Nature Genetics
    Volume: 49, P: 795-800